Agilent Technologies, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended April 30, 2018. Agilent provides instruments, software, services and consumables for life sciences, diagnostics and applied chemical markets. Amounts are in U.S. dollars; financial statements are unaudited.
Financial performance and position
- Revenue: Q2 revenue was $1.206 billion, up 9% year over year; first-half revenue was $2.417 billion, up 11%. Foreign exchange added approximately 4 percentage points to growth in both periods.
- Profit: Q2 operating income was $215 million versus $201 million; net income was $205 million versus $164 million, and diluted EPS was $0.63 versus $0.50. First-half operating income rose to $454 million from $407 million, but the company recorded a $115 million net loss versus $332 million net income in the prior year, principally due to a $533 million Tax Act charge.
- Margins: Q2 gross margin was 53.4% versus 53.7%, and operating margin was 17.8% versus 18.2%. For the first half, gross margin improved to 54.5% from 53.8%, while operating margin was 18.8% in both periods.
- Cash flow: First-half operating cash flow was $518 million, up from $373 million. Investing cash outflow was $117 million and financing cash outflow was $77 million. Capital expenditures were $108 million; management expected approximately $200 million for fiscal 2018.
- Liquidity and debt: Cash and equivalents were $3.011 billion at April 30, compared with $2.678 billion at October 31, 2017. Current assets were $4.525 billion and current liabilities $1.365 billion. Debt comprised $315 million outstanding under the revolving facility and $1.800 billion of long-term debt. The revolver balance was repaid in May.
- Shareholder returns: First-half dividends paid were $96 million; share repurchases were $93 million. The board declared a $0.149-per-share quarterly dividend for payment in July. $517 million remained authorized under the repurchase program at period-end.
Changes versus the prior comparable period
- All three segments grew in Q2: Life Sciences and Applied Markets revenue rose 7% to $561 million; Diagnostics and Genomics rose 9% to $219 million; and Agilent CrossLab rose 13% to $426 million. CrossLab had the strongest segment growth.
- Diagnostics and Genomics margins weakened: Q2 segment gross margin fell 3 percentage points to 54.9% and operating margin fell 4 points to 20.2%. Management cited a prior-year customer cancellation payment in nucleic acids, higher pathology inventory charges, wage increases and spending.
- Q2 total gross margin was pressured by higher wages, variable pay, inventory charges and unfavorable currency effects; first-half improvement reflected volume, mix and lower manufacturing material costs, partly offset by higher expenses.
- R&D expense increased 8% in Q2 and 13% for the first half; SG&A increased 10% and 14%, respectively. Headcount was approximately 14,000, up from 12,900 a year earlier.
- Prior-year revenue and related cost classifications were revised between products and services; the reclassification had no effect on previously reported operating results.
Outlook, commentary, risks and unusual items
- Management remained optimistic about growth across most key markets, citing expected strength in pharmaceuticals and solid growth in chemicals and energy. It expected strong growth in Europe and the Americas, but more modest growth in China due to government-agency reorganization. No specific consolidated revenue or EPS guidance was provided in the supplied filing text.
- Management highlighted continued investment in R&D, nucleic-acid production capacity, product launches and laboratory offerings, alongside operational simplification and shareholder returns.
- The $533 million provisional Tax Act charge drove the first-half reported loss and comprised a $480 million transition-tax estimate and $53 million deferred-tax remeasurement estimate. The tax accounting remained incomplete and could change as further guidance and state tax treatment became clearer. The filing also describes a $440 million transition-tax payment obligation in its liquidity discussion; investors should reconcile this with the tax-note estimate.
- Other income included approximately $15 million from a one-time third-party settlement. Q2 revenue was affected by Lunar New Year timing and shipments recognized in Q1 rather than Q2. Foreign currency boosted revenue but increased costs and overall net exposure.
- Subsequent events included May acquisitions of Lasergen ($105 million), Genohm (approximately $40 million) and AATI (approximately $250 million), plus pending asset acquisitions expected to cost approximately $60 million combined. Agilent also repatriated $1.5 billion of foreign-held cash in May and repaid its revolver.
- Key risks include uncertain customer order timing and capital spending, competition and product execution, supply and manufacturing constraints, acquisition integration, currency exposure, tax-law interpretation and audits, and regulatory and data-privacy compliance (including GDPR). The filing reported no pending legal matters management believed likely to have a material impact. Market-risk sensitivities for hypothetical 10% adverse currency and interest-rate movements were described as immaterial.
Important facts for investors to verify
- Reconcile the $480 million transition-tax estimate in the tax note with the $440 million payment obligation cited in the liquidity discussion, and monitor completion of provisional Tax Act accounting.
- Assess how much revenue growth persists after the approximately 4-percentage-point foreign-exchange benefit and whether segment margin trends, especially in Diagnostics and Genomics, improve.
- Track the cash, financing and integration effects of the completed and pending acquisitions, as well as the planned nucleic-acid capacity expansion and fiscal 2018 capital spending.
- Confirm the effect of post-quarter cash repatriation and revolver repayment on liquidity, and monitor debt service, dividends and the remaining share-repurchase authorization.
- Monitor China demand, customer order timing, currency exposure, tax audits and regulatory or data-protection developments.